ELOXD — Eloxx Pharmaceuticals, Inc.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1035354 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,795,000 | -3,754,000 | 8,503,000 | 6,363,000 | 16,087,000 |
| Mar 2025 | 0 | — | -1,222,000 | -1,709,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,249,000
Investing CF
—
Financing CF
$6,166,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.83
As of
2026-06-14
Balance + Analyst (yfinance extras)
Retained Earnings
$-304,334,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-4,951,000
Pretax Income TTM
$-5,463,000
Interest Exp TTM
$512,000
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -6,438,000 | -5,995,000 | 5,270,000 | 17,177,000 | — | -6,327,000 |
| Dec 2024 | 6,359,000 | -2,468,000 | -3,143,000 | 2,976,000 | 27,311,000 | — | -4,715,000 |
| Dec 2023 | 0 | -17,288,000 | -17,054,000 | 1,712,000 | 24,311,000 | — | -14,341,000 |
| Dec 2022 | 0 | -34,419,000 | -36,065,000 | 21,123,000 | 31,783,000 | — | -31,845,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $191.70B | $355.20 | — |
| GILD | GILEAD SCIENCES, INC. | $155.93B | $125.59 | — |
| ARGX | ARGENX SE | $55.57B | $893.52 | — |
| RVMD | Revolution Medicines, Inc. | $32.71B | $153.87 | — |
| BIIB | BIOGEN INC. | $29.53B | $200.05 | — |
Recent Insider Activity
No insider activity indexed for this ticker.